Amiodarone: Loading, Maintenance Dosing and Monitoring Schedule

Pharmacokinetic Considerations Relevant to Dosing

Amiodarone exhibits highly variable and complex pharmacokinetics that profoundly influence its dosing strategies. The drug is slowly and incompletely absorbed after oral administration, with systemic bioavailability ranging from 25% to 65% and minimal hepatic first-pass extraction. Following a single oral dose, plasma concentrations peak within 3 to 6 hours.

The agent undergoes extensive hepatic metabolism, yielding desethylamiodarone as a major active metabolite. Both the parent drug and its metabolite accumulate extensively in various tissues, including the liver, lung, fat, and skin, with myocardial concentrations reaching 10 to 50 times those found in plasma. Plasma clearance is low, renal excretion is negligible, and doses do not require reduction in patients with renal disease; neither amiodarone nor desethylamiodarone is dialyzable. The volume of distribution is large, averaging 60 L/kg, and the drug is highly protein-bound (96%).

The elimination half-life is multiphasic. An initial 50% reduction in plasma concentration occurs 3 to 10 days after discontinuation, representing elimination from well-perfused tissues. This is followed by a terminal half-life of 26 to 107 days (mean 53 days, with most patients in the 40- to 55-day range). Because of this prolonged terminal half-life, achieving steady-state concentration without a loading dose takes approximately 265 days. Interpatient variability mandates close clinical monitoring.

The onset of action depends on the route of administration. Intravenous (IV) amiodarone generally acts within 1 to 2 hours. Oral onset is delayed, typically requiring 2 to 3 days, and often 1 to 3 weeks or occasionally longer; loading doses mitigate this delay. During chronic therapy, plasma concentrations correlate well with oral doses, averaging approximately 0.5 mg/L (0.5 µg/mL) for each 100 mg/day at doses between 100 and 600 mg/day. Therapeutic serum concentrations range from 0.5 to 1.5 µg/mL, though greater arrhythmia suppression may occur up to 3.5 µg/mL at the cost of increased toxicity risk. In routine clinical practice, amiodarone plasma levels are rarely useful, as myocardial concentration—which correlates best with total cumulative dose—may be a better predictor of long-term tolerability.

Hemodynamic Effects

Amiodarone acts as a peripheral and coronary vasodilator. When administered intravenously (150 mg over 10 minutes followed by 1 mg/min), it decreases heart rate, systemic vascular resistance, and left ventricular dP/dt. Oral doses sufficient to control arrhythmias do not depress left ventricular ejection fraction (LVEF), even in patients with reduced LVEF. However, due to its antiadrenergic actions, IV amiodarone must be administered cautiously to patients with marginal cardiac compensation, as it may induce hypotension.

Loading Dosing Strategies

There is no standard dosing schedule applicable to all patients; the regimen must be individualized based on the clinical situation and arrhythmia severity. Because of the drug's unusual pharmacokinetics, serious arrhythmia indications, and potential adverse effects, consideration should be given to initiating therapy with the patient hospitalized and monitored for at least several days.

Intravenous Loading

For emergencies requiring rapid loading and effect, IV amiodarone is administered as an initial dose of 15 mg/min for 10 minutes. This is followed by a slower infusion of 1 mg/min for 6 hours, and then 0.5 mg/min for the remaining 18 hours and subsequent days as necessary. Supplemental infusions of 150 mg over 10 minutes can be utilized for breakthrough ventricular tachycardia (VT) or ventricular fibrillation (VF). IV infusions can be safely continued for 2 to 3 weeks. IV amiodarone is generally well tolerated, even in patients with left ventricular dysfunction, though those with depressed ejection fraction should receive it with great caution due to the risk of hypotension. Peripheral IV administration for >24 hours can cause severe thrombophlebitis.

Oral Loading

A recommended oral loading approach consists of 800 to 1200 mg/day for 1 to 3 weeks, followed by 400 to 800 mg/day for 1 to 2 weeks, before transitioning to maintenance dosing. High-dose oral loading (800 to 2000 mg/day to maintain trough serum concentrations of 2 to 3 µg/mL) may suppress ventricular arrhythmias in 5 to 7 days. Alternatively, rapid oral loading can be achieved with 2.4 to 3.0 g/day. Therapeutic drug concentrations during loading are typically between 1.0 and 2.5 µg/mL, and levels above 3.5 µg/mL are associated with a higher risk for toxicity.

Maintenance Dosing

After the loading phase (typically 2 to 3 months of treatment), a maintenance dose of 200 mg/day is generally recommended. Maintenance dosing can be administered once or twice daily and should be titrated to the lowest effective dose to minimize side effects, as drug toxicity is both dose- and duration-dependent. Doses as low as 100 mg every other day may be effective in some patients. Many supraventricular arrhythmias can be managed successfully with ≤200 mg/day, whereas ventricular arrhythmias generally require higher doses. Adverse effects are less common at ≤200 mg/day but can still occur.

Clinical Indications

Amiodarone blocks multiple cardiac ionic currents and possesses sympatholytic activity. It is the most effective antiarrhythmic drug for suppressing ventricular arrhythmias and is utilized across a wide spectrum of supraventricular and ventricular tachyarrhythmias in adults, children, and in utero. Efficacy ranges from 60% to 80% for supraventricular tachyarrhythmias and 40% to 60% for ventricular tachyarrhythmias.

Ventricular Arrhythmias and Cardiac Arrest

IV amiodarone is recommended in the 2015 ACLS algorithm for shockable rhythms (VF/pulseless VT). It may improve outcomes in patients with ventricular tachyarrhythmias during and after resuscitation from cardiac arrest. Bolus therapy (150 mg followed by a maintenance dose over 18 hours and for several days if necessary) is recommended. In trials comparing amiodarone to placebo or lidocaine, both active drugs improved survival to hospital admission compared with placebo, though no difference was observed in survival to discharge or favorable neurologic status. In the subgroup with bystander-witnessed arrest, survival to discharge was improved with both drugs.

For sustained VT or VF more than 24 to 48 hours after successful reperfusion, antiarrhythmic therapy (most often amiodarone) is generally continued until a defibrillator is placed. In patients with an implantable cardioverter-defibrillator (ICD), amiodarone reduces the frequency of shocks. It has little effect on pacing thresholds but typically increases the electrical defibrillation threshold modestly and can slow the rate of VT, occasionally below the ICD detection rate. Careful patient assessment and device reprogramming may be necessary.

Atrial Fibrillation and Flutter

Amiodarone is superior to Class I antiarrhythmic drugs and sotalol in maintaining sinus rhythm in patients with recurrent atrial fibrillation (AF). It is recommended for patients with AF and heart failure with reduced ejection fraction (HFrEF) requiring long-term antiarrhythmic drug therapy (Class I, Level A). In the perioperative setting, IV amiodarone has a limited and delayed effect for pharmacological cardioversion but can slow the heart rate within 12 hours. It can be used as first-line therapy for rate control in patients with AF and heart failure (HF), and as an alternative to control rate in atrial flutter, especially in critically compromised patients. Perioperative amiodarone is recommended to prevent post-operative AF after cardiac surgery (Class I, Level A), yielding a 58% risk reduction in meta-analysis.

Acute Coronary Syndromes

In patients with acute coronary syndromes (ACS), IV amiodarone is recommended for rate control when needed in the presence of acute HF without hypotension (Class I, Level C). It is also recommended to facilitate electrical cardioversion and decrease the risk of early AF recurrence after electrical cardioversion in unstable patients with recent-onset AF (Class I, Level C). For polymorphic VT and/or VF in the ACS setting, IV beta-blockers and/or amiodarone are recommended unless contraindicated (Class I, Level B).

Adverse Effects

Adverse effects are reported by approximately 75% of patients treated for 5 years, compelling drug discontinuation in 18% to 37% of cases. Most adverse effects are reversible with dose reduction or cessation.

Pulmonary Toxicity

Pulmonary toxicity is the most serious noncardiac adverse reaction, occurring in approximately 1% of patients. Symptoms include dyspnea and nonproductive cough, accompanied by fine crackles, hypoxia, abnormal gallium scan results, reduced carbon monoxide diffusion capacity (DLco), and radiographic pulmonary infiltrates. If pulmonary changes occur, amiodarone must be discontinued immediately; corticosteroids may be tried, though unsupported by controlled studies. Unrecognized pulmonary involvement can progress, carrying up to a 10% mortality. Risk factors include advanced age, high maintenance doses, and reduced predrug DLco. An unchanged DLco on therapy may be a negative predictor of toxicity. At maintenance doses <200 mg/day, pulmonary toxicity is uncommon but possible.

Hepatic Toxicity

Asymptomatic elevations in liver enzyme levels occur in most patients. Amiodarone should not be stopped unless values exceed two to three times the upper limit of normal in a patient with initially normal values. Cirrhosis occurs infrequently but may be fatal.

Thyroid Toxicity

Due to its iodine content, amiodarone causes hyperthyroidism (1% to 2%) or hypothyroidism (2% to 4%). The drug inhibits the peripheral conversion of T4 to T3, leading to a slight increase in T4, reverse T3, and thyroid-stimulating hormone (TSH), and a slight decrease in T3. Reverse T3 concentration can be used as an index of drug effect. In hypothyroidism, TSH increases greatly, whereas T3 increases in hyperthyroidism.

Neurologic and Ocular Toxicity

Neurologic toxicities are common, dose- and duration-related, and include tremor, ataxia, peripheral neuropathy, and rarely myopathy and encephalopathy. Lowering the dose frequently decreases severity. Corneal microdeposits occur in almost 100% of adults receiving the drug longer than 6 months. Serious ocular reactions such as optic neuritis and atrophy with visual loss are rare and causation is not firmly established.

Cardiac Toxicity

Cardiac side effects include symptomatic bradycardias in approximately 2% of patients. Torsades de pointes occurs rarely (1% to 2%) despite QT prolongation, presumably due to inhibition of multiple K channels and L-type Ca channels.

Drug Interactions

When given concomitantly with amiodarone, doses of warfarin, digoxin, and other antiarrhythmic drugs should be reduced by one-third to half with close observation. Synergistic drugs such as beta blockers or calcium channel blockers must be given cautiously. Dabigatran and edoxaban interact with amiodarone; switching to rivaroxaban should be considered.

Pregnancy

Amiodarone is categorized as Class D. It crosses the placenta (10% to 50%) and is found in breast milk. It should be avoided during breastfeeding and used in pregnant patients only if no alternatives exist. It is not recommended in pregnancy for supraventricular tachycardia management (Class III, Level C), though it may be considered for potentially life-threatening SVT when other therapies fail (Class IIa, Level C).

Monitoring Schedule

Systematic monitoring is critical during chronic therapy. The lowest possible effective maintenance dose should be used to avoid significant adverse effects. The following table summarizes the recommended outpatient follow-up.

Clinicians must remain aware of numerous drug interactions and contraindicated concomitant medications, particularly drugs that prolong the QT interval or interact with amiodarone metabolism.